APA

Awada A. H., Dumez H., Hendlisz A., Wolter P., Besse-Hammer T., Uttenreuther-Fischer M., Stopfer P., Fleischer F., Piccart M. & Schöffski P. (20131126). Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. : Investigational new drugs.

Chicago

Awada A H, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M and Schöffski P. 20131126. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. : Investigational new drugs.

Harvard

Awada A. H., Dumez H., Hendlisz A., Wolter P., Besse-Hammer T., Uttenreuther-Fischer M., Stopfer P., Fleischer F., Piccart M. and Schöffski P. (20131126). Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. : Investigational new drugs.

MLA

Awada A H, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M and Schöffski P. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. : Investigational new drugs. 20131126.